Export

ATC codes: J01XA01
EMLc
Indication
Neutropenia ICD11 code: 4B00.0Z
INN
Vancomycin
Medicine type
Chemical agent
Antibiotic groups
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection ; 500 mg in vial (as hydrochloride) powder for injection ; 1 g in vial (as hydrochloride) powder for injection
EML status history
First added in 2017 (TRS 1006)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Expert Committee recommendation
The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc. - the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.
EML recommendations: Neutropenia
First choice
Second choice
low-risk
high-risk